Summary
GE HealthCare Technologies Inc. (GEHC) reported a 7% increase in total revenues for the fiscal year ended December 31, 2023, reaching $19.55 billion. This growth was driven by broad-based strength across its four key segments: Imaging, Ultrasound, Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment, the largest contributor, saw a 6% revenue increase, while PDx demonstrated robust 18% growth. Net income attributable to GE HealthCare decreased by 18% to $1.57 billion, primarily due to increased operating expenses related to its standalone company status and higher interest expenses following its separation from GE. Despite the net income dip, the company generated strong free cash flow of $1.72 billion, underscoring its operational efficiency and ability to manage cash. GE HealthCare continues to invest in research and development, with a focus on digital solutions and AI, positioning itself for future growth in the evolving healthcare landscape. Financially, the company ended the year with $2.50 billion in cash and cash equivalents. GEHC's total debt increased to $9.44 billion, largely due to financing activities related to its 2023 spin-off from GE. Management expressed confidence in the company's liquidity, believing existing cash, operating cash flow, and credit facilities will be sufficient to meet its needs for the next 12 months. The company also continues to navigate global economic and geopolitical uncertainties, as noted in its risk factors, but its diversified product portfolio and global reach provide a degree of resilience.
Financial Highlights
51 data points| Revenue | $19.55B |
| Gross Profit | $7.92B |
| R&D Expenses | $1.21B |
| SG&A Expenses | $4.28B |
| Operating Expenses | $5.49B |
| Operating Income | $2.44B |
| Net Income | $1.57B |
| EPS (Basic) | $3.05 |
| EPS (Diluted) | $3.03 |
| Shares Outstanding (Basic) | 455.00M |
| Shares Outstanding (Diluted) | 458.00M |
Key Highlights
- 1Total revenues grew 7% to $19.55 billion in 2023, with organic revenue growth of 8%, demonstrating strong underlying business performance.
- 2The Pharmaceutical Diagnostics (PDx) segment was a standout performer, with revenue increasing by 18%, driven by price increases and improved demand.
- 3Net income attributable to GE HealthCare decreased by 18% to $1.57 billion, impacted by increased operating expenses and higher interest expenses post-spin-off.
- 4Free cash flow remained robust at $1.72 billion, reflecting effective cash generation from operations.
- 5The company ended 2023 with a healthy cash balance of $2.50 billion, supporting its liquidity needs.
- 6GEHC is actively managing its debt, which increased to $9.44 billion, largely due to spin-off financing, while maintaining compliance with debt covenants.
- 7Significant investments in R&D and a focus on digital solutions, including AI, indicate a strategic commitment to future innovation and market positioning.